Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):972-5. doi: 10.1016/j.ijrobp.2003.09.096.


A Phase I/II clinical trial was undertaken between January 29, 1987 and January 25, 1997 to assess the efficacy of (125)I-labeled monoclonal antibody 425 ((125)I-MAb 425) in controlling high-grade brain gliomas. A total of 180 patients diagnosed with glioblastoma multiforme (GBM) and astrocytoma with anaplastic foci (AAF) were administered (125)I-MAb 425 as an adjuvant treatment. All underwent initial surgery followed by postoperative external beam radiation therapy and a cumulative dose of 140 mCi of (125)I-MAb 425. Biodistribution of radioactivity after antibody administration showed increased uptake in brain tumor cells due to enhanced expression of epidermal growth factor receptors. A longer half-life of (125)I-MAb 425 in brain tumor cells compared to blood was observed. All patients were followed up for at least 5 years. Overall actuarial survival range for GBM and AAF patients showed 4-150 and 4-270 months, respectively. GBM and AAF patients under age 40 years with a Karnofsky performance status >70 had an actuarial median survival of 22.5 and 65 months, respectively. This adjuvant therapy demonstrates a significant increase in median survival and should be considered in the management of high-grade brain gliomas.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Astrocytoma / radiotherapy*
  • Astrocytoma / surgery
  • Brain Neoplasms / radiotherapy*
  • Brain Neoplasms / surgery
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • ErbB Receptors / antagonists & inhibitors*
  • Follow-Up Studies
  • Glioblastoma / radiotherapy
  • Glioblastoma / surgery
  • Humans
  • Iodine Radioisotopes / therapeutic use*
  • Radioimmunotherapy / methods*
  • Radiotherapy, Adjuvant
  • Survival Analysis


  • Antibodies, Monoclonal
  • Iodine Radioisotopes
  • ErbB Receptors